Mesoblast Completes Treatment in Phase 3 Low Back Pain Trial
New York, USA / Melbourne, Australia August 17, 2026: Mesoblast Limited has completed patient treatment in its pivotal Phase...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
New York, USA / Melbourne, Australia August 17, 2026: Mesoblast Limited has completed patient treatment in its pivotal Phase...
NEW YORK and MELBOURNE, July 13-14, 2026 Mesoblast Limited announced that it has achieved its target of treating at...
